Document Detail


Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
MedLine Citation:
PMID:  23030309     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Candesartan is a long-acting and selective nonpeptide AT(1) subtype angiotensin II receptor antagonist. The aim of this study was to compare the pharmacokinetics and to evaluate the bioequivalence of two candesartan cilexetil 16 mg formulations. Forty healthy volunteers were randomly assigned into two groups. After a single dose of 16 mg candesartan cilexetil oral administration, blood samples were collected at specific time intervals from 0-36 h. The plasma concentrations of candesartan cilexetil were determined by LC-MS/MS. The pharmacokinetic parameters such as AUC(last), AUC(inf) and C(max) were calculated and the 90% confidence intervals of the ratio (test/reference) pharmacokinetic parameters were obtained by analysis of variance on logarithmically transformed data. The mean for AUC(last) in the reference and the test drug were 1530.1 ± 434.6 and 1315.7 ± 368.6 ng·h/mL. The mean for AUC(inf) in the reference and the test drug were 1670.0 ± 454.5 and 1441.2 ± 397.8 ng·h/mL. The mean value for C(max) in the reference and the test drug was 142.6 ± 41.0 and 134.9 ± 41.4 ng/mL. The 90% confidence intervals for the AUC(last), AUC(inf) and C(max) were in the range of log 0.81-log 0.91, log 0.81-log 0.91 and log 0.88-log1.01, respectively. No adverse events were reported by subjects or found on analysis of vital signs or laboratory tests. This single dose study found that the test and reference products met the regulatory criteria for bioequivalence in these health volunteers. Both formulations were safe and well tolerated in 16 mg of candesartan cilexetil hydrochloride.
Authors:
Ji-Young Jeon; Yong-Jin Im; Yunjeong Kim; Su-Mi Han; Myeong-Jin Jo; Dae-Hee Shin; Ji-Seok Yoo; Byung-Kwan Moon; Byoung-Ki Kim; Byung-Hoon Lee; Yoon-Ho Choi; Beom-Sik Cho; Han-Young Jang; Soo-Wan Chae; Min-Gul Kim
Related Documents :
24629989 - Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carot...
23770339 - Nk1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of...
23566639 - Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: ...
16416159 - Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behav...
8021329 - Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and b...
18447779 - Evaluation of the diffusion of corticosteroids between the distal interphalangeal joint...
22907029 - Systemic dexamethasone for the prevention of cisplatin-induced ototoxicity.
670029 - Vagal and aerosol histamine interactions on airway responses in dogs.
2867079 - Use of yohimbine and 4-aminopyridine to antagonize xylazine-induced immobilization in n...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  Drug development and industrial pharmacy     Volume:  -     ISSN:  1520-5762     ISO Abbreviation:  Drug Dev Ind Pharm     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802620     Medline TA:  Drug Dev Ind Pharm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Clinical Trial Center, Chonbuk National University Hospital , Jeonju-si, Jeollabuk-do , Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vivo imaging of glia activation using (1) H-magnetic resonance spectroscopy to detect putative bi...
Next Document:  Application of ?-N-acetylgalactosaminidase and ?-galactosidase in AB to O red blood cells conversion...